ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,26%
Bitcoin
66.835,88
2,45%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BioMarin Pharmaceutical Inc (BMRN)

  7. BioMarin Pharmaceutical Inc (BMRN) News

BMRN

BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BMRN
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202423h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
13/05/202421h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
13/05/202421h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
10/05/202416h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
09/05/202416h54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
08/05/202414h00PR Newswire (US)BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVNASDAQ:BMRNBioMarin Pharmaceutical Inc
07/05/202423h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
06/05/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
06/05/202422h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/05/202422h00PR Newswire (US)New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/04/202422h03PR Newswire (US)BioMarin Reports Record Financial Results for the First Quarter 2024NASDAQ:BMRNBioMarin Pharmaceutical Inc
10/04/202414h00PR Newswire (US)BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
12/03/202413h30PR Newswire (US)New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
08/03/202400h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
07/03/202423h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
07/03/202423h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
07/03/202414h30PR Newswire (US)BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial OfficerNASDAQ:BMRNBioMarin Pharmaceutical Inc
06/03/202418h04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/03/202422h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/03/202420h41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/03/202418h04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
01/03/202415h00PR Newswire (US)BioMarin Scheduled to Participate in March Investor ConferencesNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/02/202423h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/02/202423h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/02/202423h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/02/202423h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/02/202423h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/02/202423h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
27/02/202416h35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
26/02/202419h34Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BMRNBioMarin Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:BMRN

Kürzlich von Ihnen besucht

LBNK
SLCUSDT
Solice
AMEX
BBHY
JPMorgan BetaBuilders US...
BIT
PSGVQ
Global Value Equity
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten